Informing the pharmaceutical and biotech industry.
Industry Standard Research (ISR) today announced the availability of their latest report, “Hepatitis C: Social Media, Search, and Market Analysis,” providing a product and pipeline analysis of the Hepatitis C market, as well as a never before seen in-depth social media and search analysis detailing how individuals discuss and search for Hepatitis C information, where they go to find it, and how their search progresses.
“Hepatitis C is the leading cause of liver cancer in the US and is believed to affect 170–200 million individuals worldwide” explained Andrew Schafer, President of ISR. “Given the ups and downs in recent weeks, expectations for Hep C treatments remain high. This report gives both clinical development and brand managers information they need to meet these expectations.”
ISR’s report includes a social media and search analysis of Hepatitis C.
“The analysis of natural search engine ranking pages (SERPs) of commonly searched keyword phrases in the Hep C search continuum uncovered a gap in what information users were searching for and what they expected to receive,” Schafer explained. “With few products available, this gap represents a tremendous opportunity for a drug maker to assert themselves as the information resource for Hepatitis C.”
ISR’s report also provides a disease overview; profile of current products and companies in the market; addressable market; and in-depth analysis of clinical trial activity, including 707 trials that are on-going or have been completed in the past two years to provide further understanding of Hepatitis C clinical development environment and trends. Analysis includes the number of trials by phase, the average enrollment, the average length of the studies, the sponsor type, and the types of studies being run.
The report profiles the products and pipelines of 10 companies, including Achillion, BMS, Boehringer Ingelheim, Genentech/Roche, Gilead Sciences, Idenix, Johnson & Johnson, Merck, Novartis, and Vertex.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.